メニュー

業績

受賞歴

  • 2010年　浜松医科大学若手研究支援事業　採択
  • 2011年 　第36回公益財団法人臨床薬理研究振興財団研究奨励金　採択
  • 2013年　発酵研究所研究者留学助成　採択
  • 2018年　若手研究者国際学会発表支援　採択
  • 2019年　静岡赤十字病院　院長賞　受賞
  • 2022年　静岡赤十字病院　功労賞　受賞

学会および研究会の座長、発表

座長

  • 2021/9/25　第27回日本ヘリコバクター学会学術集会　一般演題2　H. pylori除菌率
  • 2021/11/24　第27回静岡消化器癌セミナー　特別講演
  • 2022/4/25　静岡消化器内視鏡オンラインセミナー　一般演題
  • 2022/7/1　第2回基礎から学ぶ肝炎の会　一般演題
  • 2022/7/20　静岡県中部 IBD Seminar　一般演題

発表

  • 2017　日本消化器関連学会週間　ポスター発表
  • 2018　胃病態機能研究会　シンポジウム発表
  • 2018　日本カプセル内視鏡学会学術集会　シンポジウム発表
  • 2018　Digestive Disease Week(DDW)米国　Oral Presentation
  • 2018　日本ヘリコバクター学会学術集会　シンポジウム発表
  • 2018　日本消化器内視鏡学会総会　ワークショップ発表
  • 2018　浜松消化器病研究会　レクチャー発表
  • 2019　日本消化器病学会　シンポジウム発表
  • 2022　静岡消化器がん講演会　Discussant
  • 2022　 Pancreatic Cancer Meeting in Suruga　Discussant
  • 2022　IBD Academy　Panelist　

メディア

  • 2020/2/25　静岡新聞　【診察室】　寄稿
  • 2021/6/6　SBSラジオ　サンデークリニック　出演

論文

自著英文(原著のみ)

  • Uotani T, Sugimoto M, Nishino M, Kodaira C, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Tanaka T, Umemura K, Watanabe H, Miyajima H, Furuta T. Ability of Rabeprazole to Prevent Gastric Mucosal Damage from Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype. Clin Gastroenterol Hepatol 10; 879-995: 2012
  • Uotani T, Sugimoto M, Nishino M, Ichikawa H, Sahara S, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. J Clin Pharmacol. 54(8); 858-64: 2014
  • Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 19(12):1637-50: 2015
  • Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med.;3(1):9: 2015
  • Uotani T, Sugimoto M, Ichikawa H, Tanaka S, Nagashima H, Uchida T, Graham DY, Yamaoka Y. Prostate stem cell antigen gene TT genotype and development of intestinal metaplasia in Helicobacter pylori infection. J Dig Dis. 17(1):20-7: 2016
  • Uotani T, Murakami K, Uchida T, Tanaka S, Nagashima H, Zeng X, Akada J, Estes M, Graham DY, Yamaoka Y. Changes of tight junction and interleukin-8 expression using a human gastroid monolayer model of Helicobacter pylori infection. Helicobacter 2019 Jun;24(3):e12583.

自著和文(原著のみ)

  • 魚谷貴洋、杉本光繁、市川仁美、佐原秀、山出美穂子、古田隆久【低用量アスピリンによる消化管粘膜傷害研究の進歩】 低用量アスピリン起因性胃粘膜傷害におけるHelicobacter pylori感染の影響. 消化器内科. 55巻3号; 287-291: 2012
  • 魚谷貴洋、杉本光繁、古田隆久【薬剤起因性消化管傷害Update】 低用量アスピリンの上部消化管傷害　胃内pH、ヘリコバクター感染症からみた傷害発症機序(解説/特集). 医学のあゆみ. 243巻11-12号; 947-951: 2012
  • 魚谷貴洋、杉本光繁、鏡　卓馬、市川仁美、佐原　秀、古田隆久　個別化医療へ向けた低用量アスピリン起因性胃粘膜傷害に対するリスク予測、臨床薬理の進歩 No.35 87-94, 2014
  • 魚谷貴洋、古田 隆久【消化管の慢性炎症】 4．H. pyloriが引き起こす慢性炎症. 別冊BIO Clinica 慢性炎症と疾患. 第6巻第3号; 30-35: 2017

共著英文(原著のみ)

  • Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology. 57; 1314-9: 2010
  • Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T. Characteristics of patients with non-erosive gastroesophageal reflux disease refractory to frequent dose proton pomp inhibitor therapy. World J Gastroenterol. 17;1858-1865: 2011
  • Nishino M, Sugimoto M, Kodaira C, Yamade M, Uotani T, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in H. pylori-negative healthy volunteers. J Clin Pharmacol, 51; 1079-1086: 2011 　　　
  • Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Furuta T. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Digestion 85:9-17: 2012
  • Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Miyajima H, Furuta T. Rabeprazole 10mg qds deceases 24-hour intragastric acidity significantly more than rabeprazole 20mg bd or 40mg om overcoming CYP2C19 genotype. Aliment Pharmacol Ther 36;627-634: 2012
  • Sugimoto M, Uotani T, Nishino M, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T. Antiplatelet drugs are a risk factor for esophageal mucosal injury. Digestion, 87; 281-289: 2013　　　　　　　　　　　　　
  • Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 38(9); 1129-37: 2013
  • Nishino M, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T. Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment. Digestion. 88(2); 79-86: 2013
  • Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 29(3); 487-93: 2014
  • Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 54(3); 258-66: 2014
  • Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Kagami T, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 53(6); 571-5: 2014
  • Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K, Furuta T. Efficacy of Tailored Helicobacter pylori Eradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion. Helicobacter. 19(4); 312-8: 2014
  • Sugimoto M, Uotani T, Furuta T. Does rebamipide prevent gastric mucosal injury in patients taking aspirin and clopidogrel? Dig Dis Sci. 59(8); 1671-3: 2014
  • Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol.;70(9):1073-8. 2014
  • Kagami T, Sugimoto M, Ichikawa H, Sahara S, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19. Eur J Clin Pharmacol. 71(12):1467-75: 2015
  • Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Kagami T, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg. Digestion. 91(4):277-85: 2015
  • Sugimoto M, Sahara S, Ichikawa H, Kagami T, Uotani T, Furuta T. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy. Aliment Pharmacol Ther. Aug;42(4):477-83: 2015
  • Ichikawa H, Sugimoto M, Uotani T, Sahara S, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Miyajima H, Yamaoka Y, Furuta T. Influence of prostate stem cell antigen gene polymorphisms on susceptibility to Helicobacter pylori-associated diseases: a case-control study. Helicobacter. ;20(2):106-13: 2015
  • Furuta K, Kohata Y, Fujiwara Y, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Furuta T, Nio K, Iwakiri R, Inamori M, Kawamura O, Kusano M, Kato M, Kawami N, Iwakiri K, Takeuchi T, Higuchi K, Aimi M, Naora K, Fujimoto K, Arakawa T, Kinoshita Y. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr. ;55(3):178-83. 2015
  • Sugimoto M, Uotani T, Ichikawa H, Andoh A, Furuta T. Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan. Digestion. 93(1):24-31: 2016
  • Sugimoto M, Hasegawa T, Nishino M, Sahara S, Uotani T, Ichikawa H, Kagami T, Sugimoto K, Yamato Y, Togawa D, Kobayashi S, Hoshino H, Matsuyama Y, Furuta T. Improvement of gastroesophageal reflux disease in Japanese patients with spinal kyphotic deformity who underwent surgical spinal correction. Dig Endosc. ;28(1):50-8: 2016
  • Tanaka S, Nagashima H, Cruz M, Uchida T, Uotani T, Jimenez Abreu JA, Mahachai V, Vilaichone RK, Ratanachu-Ek T, Tshering L, Graham DY, Yamaoka Y. Interleukin-17C in Human Helicobacter pylori Gastritis.Infect Immun. Sep 20;85(10)
  • Tanaka S, Nagashima H, Uotani T, Graham DY, Yamaoka Y. Autophagy-related genes in Helicobacter pylori infection. Helicobacter. Jun;22(3) 2017.
  • Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Kagami T, Iwaizumi M, Hamaya Y, Osawa S, Sugimoto K, Umemura K. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis. Apr;43(3):333-342. 2017
  • Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol. Jan;74(1):45-52. 2018
  • Kagami T, Yamade M, Suzuki T, Uotani T, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. Clin Pharmacol Ther. May;103(5):906-913 2018
  • Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. World J Clin Cases. Dec 6;6(15):952-960. 2018
  • Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Baba S, Sugimura H, Miyajima H, Furuta T. High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy. Oncotarget. Oct 9;9(79) 2018
  • Furuta T, Baba S, Yamade M, Uotani T, Kagami T, Suzuki T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther. 2018 Aug;48(3):370-377. 2018
  • Mori T, Hamaya Y, Uotani T, Yamade M, Iwaizumi M, Furuta T, Miyajima H, Osawa S, Sugimoto K. Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma. PLoS One. 2018 Dec 7;13(12): 2018.
  • Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Baba S, Sugimura H, Murai J, Pommier Y, Furuta T. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy BMC Cancer. Nov 20;20(1):1123. 2020
  • Takeuchi T, Furuta T, Fujiwara Y, Sugimoto M, Kasugai K, Kusano M, Okada H, Suzuki T, Higuchi T, Kagami T, Uotani T, Yamade M, Sawada A, Tanaka F, Harada S, Ota K, Kojima Y, Murata M, Tamura Y, Funaki Y, Kawamura O, Okamoto Y, Fujimoto K, Higuchi K. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study) Aliment Pharmacol Ther. Mar;51(5):534-543. 2020
  • Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. Digestion. 101(6):743-751 2020
  • Nagata N Uotani T, Kaise M, et al. Identifying Bleeding Etiologies by Endoscopy Affected Outcomes in 10,342 Cases With Hematochezia: CODE BLUE-J Study. Am J Gastroenterol. Nov 1;116(11):2222-2234. 2021
  • Ishii N, Nagata N, Uotani T, Kaise M, et al. Outcomes in high and low volume hospitals in patients with acute hematochezia in a cohort study. Sci Rep. Oct 13;11(1):20373. 2021
  • Kishino T, Nagata N, Uotani T, Kaise M, et al. Endoscopic direct clipping versus indirect clipping for colonic diverticular bleeding: A large multicenter cohort study. United European Gastroenterol J. Feb;10(1):93-103. 2022
  • Suguro M, Nagata N Uotani T, Kaise M, et al. Treatment strategies for reducing early and late recurrence of colonic diverticular bleeding based on stigmata of recent hemorrhage: a large multicenter study. Gastrointest Endosc Jun;95(6):1210-1222.e12. 2022
  • Kobayashi K, Nagata N, Uotani T, Kaise M, CODE BLUE-J study collaborators et al. Effectiveness and adverse events of endoscopic clipping versus band ligation for colonic diverticular hemorrhage: a large-scale multicenter cohort study. Endoscopy Aug;54(8):735-744 2022
  • Shiratori Y , Naoki Ishii, Uotani T, Kaise M, Nagata N, et al. Timing of colonoscopy in acute lower GI bleeding: a multicenter retrospective cohort study. Gastrointest Endosc Jan;97(1):89 2023

共著和文

  • 多数により省略

HOME

▲ ページのトップに戻る

Close

HOME